Global cancer burden expected to rise by 60% by 2040

The 20th anniversary of World Cancer Day (February 4, 2020), an annual event meant to raise cancer awareness and encourage governments, oncology societies, non-governmental organizations, businesses, and individuals to take action against the global impact of the disease. This has been formed in recognition to make progress in cancer prevention, provide better access to cancer care, and to have better outcomes of survival. The goals address impact on human life, human suffering and productivity. The emphasis is on providing access of quality cancer care to all.

There is global rise in cancer burden in spite of progress in care in past 2 decades. The global cancer burden is estimated to grow to more than 29 million cases annually by 2040, assuming global rates in 2018 remain the same. Cancer is the leading or second-leading cause of death in 91 countries worldwide, and that the global cancer cases is expected to increase by 60% in 2040. That global rise in cancer burden is expected to continue to disproportionately affect low- and middle-income countries, where, in 2012, 65% of all cancer deaths globally occurred. This percentage is expected to increase to 75% by 2030.

"In addition to cancer medicines, radiotherapy is a main pillar of cancer treatment, and more than 50% of patients requiring radiotherapy in low- and middle-income countries do not have access to this treatment. Lack of trained professionals too is an issue. The “I Am and I Will” campaign is the theme for World Cancer Day across 3 years from 2019 to 2021, and it’s a theme to drive bigger impact on raising public awareness of cancer. We need to gather together individuals, communities, organizations, schools, business enterprises, and hospitals in various cities to make cancer awareness possible," says Dr Chinnababu Sunkavalli, senior robotic surgical oncologist, Apollo Cancer Institute, Jubilee Hills.

This year, the 20th anniversary of World Cancer Day promises to be the year that ignites greater dialogue and action to accelerate the reduction of unnecessary deaths from cancer globally.

Sunkavalli added,"Lack of access to oncology care is a major factor in the nearly 10 million deaths from cancer each year globally. Other barriers include masculine gender norms, feelings of shame and fear, and lack of knowledge about the early signs of cancer by patients and health-care providers. Access to care is truly a big problem. Many statistics show that survival outcomes are much worse in low-resource settings, usually because cancer is detected so late in the disease course. There is need to bridge the gap in cancer care and increase early detection and screening. We need a holistic solution to remove stigmas and social prejudices associated with cancer."

Shortages of medical equipment, including radiotherapy machines, medicines, and oncologists, are all major factors in cancer health disparities and poor cancer outcomes in low- and middle-income countries.

Reducing the cancer burden in low- and middle-income countries is very difficult because the problem is multifactorial, including a lack of access to affordable cancer treatment (eg, chemotherapy, targeted therapy, radiotherapy) and to oncology professionals.

Source:http://www.pharmabiz.com/NewsDetails.aspx?aid=120941&sid=2

Comments

Post a Comment

Popular posts from this blog

EMA validates Incyte’s MAA for retifanlimab to treat metastatic squamous cell anal carcinoma

Incyte, global biopharmaceutical company, announced the validation of the Company’s Marketing Authorization Application (MAA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell anal carcinoma (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy. The European Medicines Agency’s (EMA) validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process. “While the incidence of SCAC is increasing in Europe, treatment options for advanced disease are limited in their effectiveness, and there are no approved options once patients have progressed on standard therapy,” said Lance Leopold, M.D., Group vice president, Immuno-Oncology Clinical Development, Incyte. “The EMA validation of the MAA for retifanlimab – which follows the recent US Food & Drug Administration acceptance of our Biologics License Application for Priority R...
Read more

Tumour-targeting drug paves way for bone cancer treatment

 The treatment of osteosarcoma, the most common tumour of bone, is challenging, but a new study is offering hope to the patients with this disease. The study led by The University of  Texas MD Anderson Cancer Centre  found that a drug, known as bone metastasis-targeting peptidomimetic (BMTP-11), has potential as a new therapeutic strategy for this devastating illness. Results from the preclinical study looked at BMTP-11 alone and in combination with the chemotherapy agent gemcitabine. Although osteosarcoma is a relatively rare cancer, it is a leading disease-related cause of death in children and young adults ages 10 to 20. However, over the last 25 years, the five-year survival rate has remained unchanged, and the treatment options for these patients are few. In addition, the side effects of available treatment options often are significant and cumulative, and may cause other health problems and damage to major organs. "What's novel about this treatment is that...
Read more

Merck’s Keytruda plus platinum- and fluoropyrimidine-based chemotherapy receives US FDA nod to treat certain patients with locally advanced/metastatic esophageal or GEJ carcinoma

Merck, known as MSD outside the United States and Canada, announced that the US Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation in combination with platinum- and fluoropyrimidine-based chemotherapy. The approval is based on results from the phase 3 KEYNOTE-590 trial, which demonstrated significant improvements in overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) for Keytruda plus fluorouracil (FU) and cisplatin versus FU and cisplatin alone, regardless of histology or PD-L1 expression status. For OS and PFS, Keytruda plus FU and cisplatin reduced the risk of death by 27% (HR=0.73 [95% CI, 0.62-0.86]; p<0.0001) and reduced the risk of disease progression or death...
Read more